Certified Organic Evening Primrose Oil 500 mg

Certified Organic Evening Primrose Oil 500 mg

The best-known active constituent in evening primrose oil (EPO) is gamma-linolenic acid (GLA). GLA is an omega‑6 polyunsaturated fatty acid that exerts mild to moderate anti-inflammatory effects in the body. In addition to approximately 10% GLA, EPO also contains oleic acid (11%).
Anti-Inflammatory Effects: Evening primrose oil has mild to moderate anti-inflammatory effects, and has been shown to reduce levels of proinflammatory leukotriene B₄ and increase levels of anti-inflammatory prostaglandin E₁.
Based on its anti-inflammatory effects, EPO has been shown to be beneficial for atopy/eczema and related skin conditions, premenstrual mastalgia and breast cysts, and may also be helpful for rheumatoid arthritis.
Fatty acid profiles (blood samples) have been shown to be abnormal in women with cyclical mastalgia, with increased levels of saturated fats and decreased levels of polyunsaturated fatty acids, linoleic, dihomo-gamma-linolenic (DGLA), and arachidonic acid. Evening primrose supplementation increased DGLA levels after two and four months of supplementation.

SKU: 0123 Category:

Description

Suggested Use

Adults: Take 3 softgels one to four times daily or as directed by your health-care practitioner.

Cautions and warnings:

Ingredients

Each softgel contains:
Certified organic evening primrose (Œnothera biennis) seed oil500 mg
Providing:
gamma‑Linolenic acid (GLA) (10%)50 mg
Linoleic acid (LA) (68%)340 mg
Other ingredients: Natural vitamin E (from sunflower) in a softgel made of bovine gelatin, glycerin, and purified water.

Uses of evening primrose oil

DosenOutcomes

Eczema and Skin Conditions

Oral: 500 to 6000 mg EPO (based on age) × 5 mo65 children with eczema24 (96%) patients of EPO group and 8 (32%) patients of placebo group had improvement (p < 0.00001).
Topical EPO10 patients with 5‑Azacitidine (drug) skin reactionsReduced skin reaction to drug injection.
Meta-analysis of oral EPO for eczema: 1000 to 6000 mg/d EPO9 controlled trials including 311 patientsEPO improved the severity of eczema based on inflammation, dryness, scaliness, pruritus and overall skin involvement compared to baseline and placebo. Odds of improvement were 4.27 based on clinician global symptom rating (p < 0.0001).

PMS/Mastalgia

3000 mg/d × 6 mo85 women with premenstrual cyclical breast discomfortSignificant reduction compared to baseline (p = 0.005).
1000 mg/d × 3 mo (compared to topical NSAIDs)50 women with moderate to severe breast pain64% had a clinically significant response after three months, compared to 92% in the NSAID group.
6 capsules/d × 1 y (1440 mg GLA)200 women with confirmed breast cystsRecurrent cyst formation was non-significantly lower in the first year.

Autoimmune Arthritis

6000 mg/d (540 mg GLA) × 6 mo (compared to an equal amount of olive oil)40 patients with rheumatoid arthritis and upper gastrointestinal lesions due to NSAIDs3 patients in each group were able to decrease their pain medication dose. There was improvement in morning stiffness in the EPO group, with pain improvement also seen in the olive oil group